Tibra Equities Europe’s NextCure NXTC Stock Holding History

Tibra Equities Europe’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,425	Closed	-$330K	–	145
2021 Q2	$330K	Buy	+3,425	New	+$350K	0.1%	116

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tibra Equities Europe's NXTC Position: Q3 2021 in Review

Tibra Equities Europe sold out of NextCure (NXTC) in Q3 2021, closing a stake of 3,425 shares — an estimated $330K sold.

Tibra Equities Europe first reported a position in NXTC in Q2 2021 and held it in 1 quarter. The position peaked at $330K in Q2 2021. 71 funds tracked by Wall St. Rank hold NXTC as of Q3 2021.

Tibra Equities Europe reported no remaining NextCure position as of Q3 2021 after selling out during the quarter.
Tibra Equities Europe sold 3,425 NextCure shares in Q3 2021, an estimated $330K.
Tibra Equities Europe first reported a position in NextCure in Q2 2021 and held it in 1 quarter.
Tibra Equities Europe's NextCure position peaked at $330K in Q2 2021.
71 funds tracked by Wall St. Rank held NextCure as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.